An Open-Label Extension Study of Palovarotene Treatment in Fibrodysplasia Ossificans Progressiva (FOP)

NCT02279095 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

58

Enrollment

INDUSTRY

Sponsor class

Conditions

Fibrodysplasia Ossificans Progressiva

Interventions

DRUG: Palovarotene dose level 1
DRUG: Palovarotene dose level 2
DRUG: Palovarotene dose level 3
DRUG: Palovarotene dose level 4

Sponsor

Clementia Pharmaceuticals Inc.